Ernexa Therapeutics Inc. (ERNA) stock
ERNANasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ERNAW
$1.79−0.14 (-7.25%)
Close on Nov 12, 2026Market cap $2.92MP/E –Yield –
Ernexa Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Ernexa Therapeutics's total debt was $2.03M at Dec 31, 2020. For fiscal 2020 it was $2.03M, down 25.8% from the year before. The highest annual figure on record is $8.11M in fiscal 2016.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $2.03M | -25.8% |
| FY2019 | Dec 31, 2019 | $2.74M | -26.5% |
| FY2018 | Dec 31, 2018 | $3.73M | -26.4% |
| FY2017 | Dec 31, 2017 | $5.07M | -37.5% |
| FY2016 | Dec 31, 2016 | $8.11M | +9.0% |
| FY2015 | Dec 31, 2015 | $7.44M | +39.8% |
| FY2014 | Dec 31, 2014 | $5.32M | +233.9% |
| FY2013 | Dec 31, 2013 | $1.59M | +2175.7% |
| FY2012 | Dec 31, 2012 | $70.00K | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2020 | Dec 31, 2020 | $2.03M | -25.8% |
| Q3 FY2020 | Sep 30, 2020 | $3.35M | +12.1% |
| Q2 FY2020 | Jun 30, 2020 | $3.25M | -2.2% |
| Q1 FY2020 | Mar 31, 2020 | $1.99M | -42.8% |
| Q4 FY2019 | Dec 31, 2019 | $2.74M | -26.5% |
| Q3 FY2019 | Sep 30, 2019 | $2.99M | -26.8% |
| Q2 FY2019 | Jun 30, 2019 | $3.32M | -29.7% |
| Q1 FY2019 | Mar 31, 2019 | $3.48M | -28.9% |
| Q4 FY2018 | Dec 31, 2018 | $3.73M | -26.4% |
| Q3 FY2018 | Sep 30, 2018 | $4.08M | -22.3% |
| Q2 FY2018 | Jun 30, 2018 | $4.72M | -13.6% |
| Q1 FY2018 | Mar 31, 2018 | $4.89M | -36.9% |
| Q4 FY2017 | Dec 31, 2017 | $5.07M | -37.5% |
| Q3 FY2017 | Sep 30, 2017 | $5.25M | – |
| Q2 FY2017 | Jun 30, 2017 | $5.46M | – |
| Q1 FY2017 | Mar 31, 2017 | $7.75M | – |
| Q4 FY2016 | Dec 31, 2016 | $8.11M | – |
See a number that looks wrong?